Eisai Selects Soleo Health as Specialty Pharmacy Provider for Leqembi
Soleo Health will distribute Leqembi, the newly approved Alzheimer's therapy, to provider offices and infusion centers, as well as administer it across its own ambulatory infusions centers.
Soleo Health has been selected by Eisai as the sole specialty pharmacy distribution partner for Leqembi (lecanemab-irmb) to treat patients with Alzheimer’s disease. Leqembi is an anti-amyloid monoclonal antibody used to treat patients with mild cognitive impairment and mild Alzheimer’s disease. The FDA granted accelerated approval to the therapy on Jan. 6, 2023.
Related: FDA Approves Alzheimer’s Medication Lecanemab
Patients will be supported through Soleo Health’s Alzheimer’s Disease Therapeutic Care Management Center, which is staffed with interdisciplinary teams comprising experienced physician specialists, nurse practitioners, therapy-care pharmacists, registered nurses, reimbursement specialists and patient care ambassadors. Soleo Health has locations nationwide with pharmacy licensure in all 50 states.
Soleo Health will distribute Leqembi to provider offices and infusion centers, as well as administer it across its own ambulatory infusions centers, including those owned and operated through its provider division, Virtis Health.
Eisai and its partner Biogen have submitted a supplemental BLA seeking full approval for Leqembi based on data from the phase 3 confirmatory trial Clarity AD.
Iowa Expands PBM Legislation to Address Concerns of Independent Pharmacies
May 16th 2025A new law in Iowa, if signed by the governor, will mandate 100% pass-through of rebates, increased financial transparency, and a minimal payment for pharmacies. Critics say it will be the most costly mandate in the state’s history.
Read More
Is Arkansas’ New PBM Law the Right Path Forward for Reform? No One Knows Yet
May 9th 2025It could improve access to community pharmacies and lower prices. Or it will limit access to critical drugs and impact payers’ ability to contract for a broad range of services. Industry leaders are unsure about the impact of Arkansas’ law banning PBMs from owning pharmacies.
Read More
